默克是一家蓝筹股，提供防御性医疗保健敞口，具有一致的盈利、强劲的资产负债表，以及通过研发和战略收购进行创新的成熟能力。
默克是一家制药巨头，以Keytruda为支撑（世界顶级肿瘤学药物），兼具强大的产品管线和数十年可靠的派息记录。
默克是由Keytruda驱动的制药巨头——全球最畅销的癌症免疫疗法——在肿瘤学、疫苗和动物健康领域拥有多元化的产品管线。
默克是全球最重要的制药股票之一，以Keytruda为支撑——全球最畅销的癌症药物——在肿瘤学、疫苗和心脏代谢疾病领域拥有深厚的产品管线。
Data updated Feb 15 · Source: Twelve Data
Merck has delivered exceptional performance, trading near its 52-week high of $123.33 with a remarkable 59% gain over six months and 42% over the past year. The stock's momentum is strong, sitting well above its 50-day moving average of $108. At a P/E of 14.88 with EPS of $8.16, Merck offers compelling value relative to pharma peers.
The bull case centers on Keytruda, the world's top-selling drug, along with a diversified pipeline spanning oncology, vaccines, and animal health. Merck's acquisition strategy (notably Prometheus Biosciences and recent deals) strengthens its post-Keytruda outlook. Financial health remains robust with consistent free cash flow generation.
The bear case involves Keytruda's patent cliff around 2028, which represents roughly 50% of pharmaceutical revenue. Pipeline execution risk and pricing pressures from potential Medicare negotiations add uncertainty. While Merck has raised its dividend for over a decade, the yield remains modest compared to true dividend aristocrats.
Overall, Merck represents a well-managed pharmaceutical giant with near-term strength but meaningful long-term transition risk that investors should monitor closely.
Merck stands as a formidable player in the global healthcare landscape, anchored by its dominant oncology franchise, particularly Keytruda, and a resilient animal health business. Trading near its 52-week high of $122.66, the stock has shown significant momentum, currently sitting well above its 50-day moving average. A P/E ratio of 25.07 suggests a premium valuation compared to some industry peers, reflecting high market expectations for its pipeline execution and recent earnings growth. While the company boasts strong cash flows and solid fundamentals, the primary risk remains its heavy revenue concentration in Keytruda and the looming patent cliff later this decade. Investors must weigh this concentration risk against Merck's aggressive M&A strategy and pipeline diversification. Overall, Merck represents a high-quality defensive holding, though the current valuation demands successful clinical outcomes to justify further upside.
Latest from Otrai
A stock index is a single number that summarizes the price action of a basket of companies. The S&P 500 tracks roughly 500 large US firms, the Nasdaq-100 tracks the 100 largest non-financial names on the Nasdaq exchange, and the Dow Jones Industrial Average follows 30 blue-chip stocks.
The Greeks explain why an option costs what it costs and how that price changes when the stock moves, time passes, and volatility shifts. Delta, Gamma, Theta, and Vega, made accessible.
Chart patterns are the most recognizable part of technical analysis and the most misunderstood. Most fail or break out the wrong way before reversing. This guide covers head and shoulders, double tops and bottoms, triangles, and flags — with realistic reliability, target measurement, and false-breakout confirmation.
每个交易员都有一个在脑子里看起来很好的策略。回测是您发现它是否实际有效的方式。以下是如何正确测试策略、哪些指标重要，以及为什么大多数回测结果好得不真实。
Powered by Rexiew